Corcept Therapeutics (CORT) Enterprise Value (2010 - 2026)

Corcept Therapeutics has disclosed Enterprise Value across 17 years of filings, most recently posting -$338.2 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$338.2 million, down 4.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$338.2 million (down 4.78% YoY), and the FY2025 annual result was -$372.2 million, up 2.92% from the prior year.
• Enterprise Value came in at -$338.2 million for Q1 2026 at Corcept Therapeutics, up from -$372.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$322.8 million in Q1 2025 to a low of -$473.2 million in Q2 2024.
• The 5-year median for Enterprise Value is -$372.2 million (2025), against an average of -$384.7 million.
• Across the five-year window, Enterprise Value plunged 93.11% in 2022 and grew 27.67% in 2025, its largest moves.
• Corcept Therapeutics' Enterprise Value stood at -$431.7 million in 2022, then increased by 14.7% to -$368.2 million in 2023, then fell by 4.1% to -$383.3 million in 2024, then advanced by 2.92% to -$372.2 million in 2025, then increased by 9.13% to -$338.2 million in 2026.
• The last three Enterprise Value figures came in at -$338.2 million (Q1 2026), -$372.2 million (Q4 2025), and -$421.7 million (Q3 2025), per Business Quant data.